The Blood and Marrow Transplant Program at Northside Hospital is a collaboration between The Blood and Marrow Transplant Group of Georgia (BMTGA) and Northside Hospital.

For questions, call (404)-255-1930

How to Refer a Patient

Physician Bios

How to Donate Blood and Platelets

New Patient Forms

Privacy Practice

Map & Directions

Employment Opportunities

Please e-mail your resume or send any questions to the following e-mail address: You may also call Marianne Silverboard at 404 255-1938 ext. 1104.

Click to help

Are You Planning to Enroll in a 2018 ACA Plan?

The exchange open enrollment period is November 1 – December 15, 2017

The following lists the insurers offering plans in Georgia and which plans BMTGA and Northside Hospital accept:


BMTGA Accepts?

Northside Hospital Accepts?



No – Transplant
Yes – Leukemia 










Please call (404)-255-1930 if you have any questions or concerns.

Advances in Immunotherapy for Cancer: Novel Phase 1 Clinical Research Trial Open for Enrollment

Click Here for Details

Ongoing Clinical Trial Evaluating the Use of Bispecific T-Cell Engaging Antibodies for targeting CD123 Expressing Cancer Cells

Acute myeloid leukemia (AML) is among the most common hematologic cancers. AML typically has a bimodal incidence, with peaks occurring in early childhood and in late adulthood. However, all age groups are affected.

Click here to read more on this story and others in the lastest BMT Newsletter

Dr. Scott Solomon to Present Multiple Myeloma: First Relapse and Beyond

Click here for more information

NSH-BMT/Leukemia Program Advanced Practice Provider Maria Hanik, DNP, APRN-BC, OCN, BMTC, will Present Role of Stem Cell Transplant in Myelofibrosis

Click here for more information

Exceeding Expectations
Immunotherapy Research Leads to Better Outcomes for Leukemia and BMT Patients

Please read Drs. Asad Bashey and Lawerence Morris’ comments on how immunotherapy research has positively impacted survival outcomes for BMT and leukemia patients. 

Join us as we celebrate blood and marrow transplant recipients, donors who saved lives, and honor the memories of those who will forever be in our hearts. 

Funds raised will support lifesaving research, assist transplant recipients, and add potential marrow donors to the registry.

Be The Match is the world’s leading nonprofit organization focused on saving lives through blood, marrow, and cord blood transplantation. For more information, please contact or 404-985-7774.

Over Performing 2009 - 2016: Survival Outcome Rates in Allogeneic Transplants

The NSH BMT Program is the only adult BMT Program in Georgia, to achieve survival outcomes that significantly exceeded the expected survival rate for allogeneic transplants for the last 8 consecutive reporting cycles (2009-2016)1,2. Over the past eight years, we believe our programs’ commitment to quality has consistently increased patient survival rates and lower treatment-related mortality rates. There were 179 adult and pediatric transplant centers included in the analysis.

Please click Survival and for additional information.

1. Reported outcome data from This survival information includes only patients who received their first allogeneic transplant between January 1, 2012 and December 31, 2014 using unrelated or related donors, and who had reported follow-up.
2. Final 2016 Transplant Center Specific Survival Report, December 12, 2016

Congratulations to Our Atlanta Top Doctors

The Blood and Marrow Transplant Group of Georgia physicians, Asad Bashey, H. Kent Holland, Lawrence Morris, and Scott Solomon, have been voted by their peers as Atlanta Top Doctors. Our Physician Team provides outstanding patient and referring physician customer service which has resulted in exceptional survival outcomes and excellent patient /referring physician satisfaction.

The Top Doctor nominating process, conducted by Castle Connolly, a healthcare research and information company founded in 1991. Castle Connolly identifies the top doctors in America and provides consumers with detailed information about their education, training, and special expertise. Its online nominations process, , is open to all U.S. licensed physicians. Doctors do not and cannot pay to be selected and profiled as Castle Connolly Top Doctors.

Please visit the Atlanta Magazine Top Doctor edition at

Peer Reviewed Article Published in Biology of Blood and Marrow Transplantation

Dr. Scott Solomon

Dr. Scott Solomon’s peer reviewed article, GVHD-Free, Relapse-Free Survival – a Dynamic Endpoint to Better Define Efficacy Following Allogenic Transplant, has been accepted for publication by the journal, Biology of Blood and Marrow Transplantation. To read Dr. Solomon’s article, please go to

Neal Brasfield, Unrelated Allogeneic Transplant Recipient, Meets His Donor at the Blood & Marrow Transplant Reunion

To view additional BMT reunion photos, please go to Survivorship

NSH-BMT Program Named as Core Clinical Transplant Center

NSH-BMT is the only transplant program in Georgia to receive the prestigious designation of Core Clinical Center from the Blood and Marrow Transplant Clinical Trials Network (BMT-CTN). This designation is accompanied by a research grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) and the National Cancer Institute (NCI). The Program is one of 20 out of more than 120 such BMT Programs in the United States to be awarded this status.


Advances in Immunotherapy for Cancer: Novel Phase 1 Clinical Research Trial Open for Enrollment

Click Here for Details

Advances in Immunotherapy for Cancer: Novel Phase 1 Clinical Research Trial Open for Enrollment

Click Here for Details

Advances in Immunotherapy for Cancer: Novel Phase 3 Clinical Research Trial Open for Enrollment

Click Here for Details

Advances in Immunotherapy for Cancer: Novel Phase 1 Clinical Research Trial Open for Enrollment

Click Here for Details

Advances in Immunotherapy for Cancer: Novel Phase 1 Clinical Research Trial Open for Enrollment

Click Here for Details

Advances in Immunotherapy for Cancer: Novel Clinical Research Trial Open at Northside Hospital’s Blood and Marrow Transplant Program

Click Here for Details

Advances in Immunotherapy for Cancer: Novel Clinical Research Trial Open at Northside Hospital’s Blood and Marrow and Transplant Program

Click Here for Details

NSH - BMT’s Clinical Program, Collection Facility and Hematopoietic Stem Cell Processing Laboratory Receives a Perfect FACT (Foundation for Accreditation of Cellular Therapy) Inspection Score

In November 2015, the NSH - BMT Clinical Program, Collection Facility (Atlanta Blood Services) and the Hematopoietic Stem Cell Laboratory underwent the required three year FACT inspection. Each area was praised for their commitment to a culture of quality, patient safety and continuously striving for high patient satisfaction. We believe our continuous process improvement, open communication and focusing on improving patient care has resulted in superior survival outcomes. NSH-BMT’s clinical program has received perfect FACT inspection scores during their 2003, 2006, 2009, 2012, and 2015 inspections.


Ashlee Holbein, RN, FACT/QI Coordinator and Melissa Horowitz, RN, Supervisor of Program Quality & Clinical Coordinators

BMT Program Quality External Audits: FACT

Consecutive Inspections Resulted in ZERO Clinical Deficiencies

The Stovall Foundation Donates Apartments to the Blood and Marrow Transplant Program

Since 2003, The Stovall Foundation, led by Ray and Martha Stovall, provides local lodging for transplant patients and their caregivers. The Stovall Foundation’s generous donations have allowed patients and their family members, who live 50 miles or greater from NSH, to be able to stay at a comfortable, high quality, safe and clean facility at no cost. All apartments are fully furnished and are located conveniently to Northside Hospital.

The Stovall’s deep commitment to community and making a difference in the lives of transplant patients and their family members has allowed our program to treat patients who may not have had the funds to travel to our program to receive lifesaving cancer treatment. Martha states, ‘Our son Kenneth had his transplant care at Northside, and we understand the many challenges treatment creates for the patient and family. We hope our apartment donations can bring comfort and solace to those families who are experiencing health and life challenges.’ We thank the Stovall’s for their long-standing support of our program.

For more information about the Stovall Foundation, please email

     Martha Stovall, Dr. Scott Solomon, Ray Stovall

Margaret Marcinkowski: Eighteen Years with the NSH BMT/Leukemia Program: A life of Hope and Wellness

Margaret's family in 1998 and in 2015

I had been feeling unwell for a few weeks. I had multiple issues, but it had come on gradually, so I wasn’t clear how sick I was. I was diagnosed with Acute Meylogenous Leukemia in June of 1998. I remember going to the hospital the night before my leukemia diagnosis. I was 36 years old, married and a mother of three small children ages 8, 5 and 1. The evening after I was diagnosed I was admitted to Northside Hospital. I was introduced to Dr. Gerry Connaghan and Dr. Kent Holland, who were opening their practice, The Blood and Marrow Transplant Group of Georgia at Northside Hospital. Suddenly, I felt like my luck was changing. I could be treated at Northside Hospital’s BMT/Leukemia programs and be treated by extraordinary experts in their field.

To read more of Margaret’s story, please click here.

Updated 2017 Referral Guidelines: Recommended Timing For Transplant Consultation

Disease stage at the time of transplant can have a significant impact on patient survival [1] appropriate planning and early donor identification are critical for optimal outcomes.

The 2017 referral timing guidelines were developed jointly by the National Marrow Donor Program® (NMDP) /Be The Match® and the American Society for Blood and Marrow Transplantation (ASBMT) and are based on current clinical practice, medical literature, and evidence-based reviews. [1,2]

The guidelines highlight disease categories that include patients at risk for disease progression, who should be referred for consultation for autologous or allogeneic HCT.[3]

If you have questions as to when to refer a patient for initial transplant consult, please call 404-255-1930 and ask to speak to one of our transplant physicians.

  1. Lee, SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007;110(13): 4576-4583. Access
  2. Pidala J, Lee SJ, Ahn KW, et al. Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. Blood. 2014:124(16):2596-2606. Access
  3. NMDP/Be The Match & ASBMT Recommended Timing for Transplant Consultation, 2017. Download (PDF) 

Post-Transplant New Mobile App is Now Available

To help physicians with the reference materials they need to care for transplant patients, BeTheMatch® has developed a free Transplant Guideline mobile app, available through the Apple© and Android™ app stores. For more information please visit nmdpapp

Post- Blood and Marrow Transplant Immunization Schedule- What You Need to Know

After blood and marrow transplant, patients will need to be re-immunized with all childhood vaccinations due to their new immune systems being immature and vulnerable to diseases/infections. It is recommended that post-transplant patients begin their vaccination schedule six months after transplant unless clinically contraindicated. The Centers for Disease Control (CDC), recommends the following:

  • Inactivated influenza vaccine should be administered beginning at least 6 months after HCT and annually thereafter for the life of the patient.
  • Sequential administration of 3 doses of pneumococcal conjugate vaccine is recommended, beginning 3-6 months after the transplant, followed by a dose of PPSV.
  • A 3-dose regimen of Hib vaccine should be administered beginning 6 months after transplant; at least 1 month should separate the doses.
  • MMR vaccine should be administered 24 months after transplant if the HCT recipient is immunocompetent.
  • If a decision is made to vaccinate with varicella vaccine, the vaccine should be administered a minimum of 24 months after transplantation if the HCT recipient is presumed to be immunocompetent.
Please click here to view the NSH-BMT post-transplant vaccination schedule recommended for both autologous and allogeneic transplant recipients. For more specific information, see Tomblyn M, Chiller T, Einsele H, et al. Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective [1.9MB, 96 pages]. Biol Blood Marrow Transplant 15:1143-1238;2009 or visit

Atlanta Blood Services, Program Collection Facility, Celebrates Donor James Arnett’s 250th Platelet Donation

James Arnett recently donated his platelets for the 250th time. To celebrate this occasion, Carrie Cox, Executive Director, Atlanta Blood Services, dedicated one of its platelet collection devices in James’ honor. For the last five years, James has donated platelets on an average of 24 times per year. His first donation was May 22, 2002, after his son’s teacher was diagnosed with cancer. All platelet donations are kept locally and used for leukemia, cancer patients, and neonatal intensive care unit infants.
To read more about James’ platelet donations, please click Neighbor News 

Platelet Donation Video - Atlanta Blood Services

Hesitant about donating platelets? Our wonderful platelet hero Dave takes the guesswork out of donating! The process is very similar to donating whole blood, and with your donation you are giving the gift of life to an active blood cancer or blood disorder patient right here in Atlanta!

Call 404-459-8744 and schedule your appointment to save lives today!

Click here to view video


The Blood and Marrow Transplant Program at Northside Hospital (NSH-BMT) provides the best of both worlds — clinical excellence and compassionate care. Committed to being the premier program in the Southeast, we provide outstanding state-of-the-art care for patients with leukemia and for those patients undergoing blood marrow and stem cell transplantation.